Overview of HCV associated HCV Infection

ID Literature Title Group
1 23095680 Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients
Mutation
2 23322644 Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B
Mutation
3 23893289 The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity
Mutation
4 23940646 Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus
Mutation
5 30061289 Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
Mutation
6 35500034 Assessing in vivo mutation frequencies and creating a high-resolution genome-wide map of fitness costs of Hepatitis C virus
Mutation
7 19412343 Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation
Mutation
8 22345449 Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis
Mutation
9 15755750 Characterizing the function and structural organization of the 5' tRNA-like motif within the hepatitis C virus quasispecies
Mutation
10 19106142 Analysis of natural variants of the hepatitis C virus internal ribosome entry site reveals that primary sequence plays a key role in cap-independent translation
Mutation
11 12477861 Structurally conserved amino Acid w501 is required for RNA helicase activity but is not essential for DNA helicase activity of hepatitis C virus NS3 protein
Mutation
12 28758632 Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo
Mutation
13 20886100 A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach
Mutation
14 20926639 The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity
Mutation
15 21829654 Generation of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature
Mutation
16 21912520 Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection
Mutation
17 22545104 Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture
Mutation
18 23696737 Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape
Mutation
19 19778418 Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry
Mutation
20 21799903 A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A
Mutation
21 37384719 An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA
Mutation
22 36680226 Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV
Mutation
23 38103659 Impact of amino acid substitutions in hepatitis C virus core region on the severe oxidative stress
Mutation
24 11906622 Single nucleotide insertion in the 5'-untranslated region of hepatitis C virus with clearance of the viral RNA in a liver transplant recipient during acute hepatitis B virus superinfection
Mutation
25 15780809 Hepatitis C virus (HCV) 5'NC sequence variants and their association with hepatitis C risk groups
Mutation
26 18941234 Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire
Mutation
27 19489073 Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A
Mutation
28 19680534 Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics
Mutation
29 20445200 Rapid emergence of protease inhibitor resistance in hepatitis C virus
Mutation
30 22654662 Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems
Mutation
31 22848441 Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir
Mutation
32 23088845 Molecular characterization of hepatitis c virus in multi-transfused Colombian patients
Mutation
33 30934020 Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs
Mutation
34 37835845 Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
Mutation
35 22024525 NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5
Mutation
36 30286205 Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir
Mutation
37 31739623 Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region
Mutation
38 31450900 The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients
Mutation
39 26562015 Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics
Mutation
40 25027573 Patients eligible for treatment with simeprevir in a French center
Mutation
41 35062220 The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures
Mutation
42 24341898 Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients
Mutation
43 31644681 Resistance mutations of NS3 and NS5b in treatment-naive patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil
Mutation
44 20565573 Evidence for separation of HCV subtype 1a into two distinct clades
Mutation
45 25140696 Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing
Mutation
46 32049405 Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents
Mutation
47 26047611 Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia
Mutation
48 26100711 Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir
Mutation
49 26317755 Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
Mutation
50 27023593 Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment
Mutation
51 27833382 Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database
Mutation
52 28588311 Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
Mutation
53 31683616 Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports
Mutation
54 35123932 The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan
Mutation
55 36197422 Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis
Mutation
56 34692891 Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens
Mutation
57 20550652 Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a
Mutation
58 27923693 Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
Mutation
59 22482443 Hepatitis C genotype 1a replicon improved through introduction of fitness mutations
Mutation
60 33808782 Comparative Analysis of Within-Host Mutation Patterns and Diversity of Hepatitis C Virus Subtypes 1a, 1b, and 3a
Mutation
61 25445400 Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
Mutation
62 22511937 Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
Mutation
63 26213689 Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors
Mutation
64 27920481 New real-time-PCR method to identify single point mutations in hepatitis C virus
Mutation
65 28270091 Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
Mutation
66 31571951 Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide
Mutation
67 32275694 Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naive HCV positive Pakistani patients
Mutation
68 34339738 Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability
Mutation
69 29895871 Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy
Mutation
70 23440108 Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
Mutation
71 27163636 Compartmentalization of hepatitis C virus variants in patients with hepatocellular carcinoma
Mutation
72 26135875 Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir
Mutation
73 26195509 Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies
Mutation
74 31366046 Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease
Mutation
75 19052239 In vitro selection of a neutralization-resistant hepatitis C virus escape mutant
Mutation
76 19171049 Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry
Mutation
77 19302336 Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles
Mutation
78 18215275 Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
Mutation
79 21056040 Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus
Mutation
80 21283512 Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection
Mutation
81 22252823 Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease
Mutation
82 24466079 HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil
Mutation
83 24768676 Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors
Mutation
84 31914458 Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus
Mutation
85 29132303 Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil
Mutation
86 30116054 Epidemic history of hepatitis C virus genotypes and subtypes in Portugal
Mutation
87 33922732 Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b
Mutation
88 27494410 Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
Mutation
89 37375444 Looking at the Molecular Target of NS5A Inhibitors throughout a Population Highly Affected with Hepatitis C Virus
Mutation
90 12615931 Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase
Mutation
91 19812153 Identification of hepatitis C virus NS5A inhibitors
Mutation
92 30081054 Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus
Mutation
93 29063860 Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor
Mutation
94 26587218 Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran
Mutation
95 21600932 Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661
Mutation
96 31646247 Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant
Mutation
97 27756381 Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis
Mutation
98 19340394 Modification of hepatitis C virus 1b RNA polymerase to make a highly active JFH1-type polymerase by mutation of the thumb domain
Mutation
99 18070954 In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
Mutation
100 34093991 Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation
Mutation
101 35693474 Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from Sao Paulo state, Brazil
Mutation
102 22995142 Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates
Mutation
103 26577836 Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naive patients with chronic hepatitis C
Mutation
104 27618896 Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naive Patients
Mutation
105 27812165 Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
Mutation
106 28489763 Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China
Mutation
107 28680115 Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naive Patients
Mutation
108 29184422 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naive hepatitis C genotype 1b-infected patients in western China
Mutation
109 29362671 The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus
Mutation
110 15117324 Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study
Mutation
111 19521536 Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations
Mutation
112 24489961 Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naive Korean patients chronically infected with HCV genotype 1b
Mutation
113 29892096 Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis
Mutation
114 40006924 Hepatitis C Virus Resistance-Associated Substitutions in Mexico
Mutation
115 25954851 Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy
Mutation
116 26878268 Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism
Mutation
117 27256744 Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older
Mutation
118 28361915 Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing
Mutation
119 31269695 NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients
Mutation
120 32656649 Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection
Mutation
121 26083687 Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay
Mutation
122 26368554 Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy
Mutation
123 26643326 Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
Mutation
124 27703205 Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents
Mutation
125 29180522 Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
Mutation
126 30941111 Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China
Mutation
127 31178495 Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis
Mutation
128 32544182 Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection
Mutation
129 12692237 Replication studies using genotype 1a subgenomic hepatitis C virus replicons
Mutation
130 14990694 Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon
Mutation
131 21060866 DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A
Mutation
132 22087316 Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals
Mutation
133 24568313 Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound
Mutation
134 28134353 Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment
Mutation
135 28135777 Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1b and advanced liver disease
Mutation
136 29599611 Daclatasvir plus asunaprevir in treatment-naive patients with hepatitis C virus genotype 1b infection
Mutation
137 29986475 Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms
Mutation
138 31201062 Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease
Mutation
139 36880209 Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea
Mutation
140 18086851 Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system
Mutation
141 19923258 Characterization of hepatitis C virus NS3 modifications in the context of replication
Mutation
142 28440885 Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b
Mutation
143 30063245 Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
Mutation
144 31589628 Subgenotyping and genetic variability of hepatitis C virus in Palestine
Mutation
145 29577052 Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context
Mutation
146 27729747 Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C
Mutation
147 25136559 Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin
Mutation
148 12393733 Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells
Mutation
149 21957306 Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA
Mutation
150 23383655 Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b
Mutation
151 24166351 Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy
Mutation
152 36016300 Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment
Mutation
153 18712792 Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation
Mutation
154 23593007 Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein
Mutation
155 27605597 Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens
Mutation
156 23913364 Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors
Mutation
157 28783119 Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents
Mutation
158 37500705 Study of drug resistance-associated genetic mutations, and phylo-genetic analysis of HCV in the Province of Sindh, Pakistan
Mutation
159 31078622 Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir
Mutation
160 38102947 Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon
Mutation
161 24321105 Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population
Mutation
162 21756947 Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease
Mutation
163 24013001 In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons
Mutation
164 33246391 Core amino acid substitutions in HCV-3a isolates from Pakistan and opportunities for multi-epitopic vaccines
Mutation
165 25994168 Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen
Mutation
166 39881992 In silico analysis of the effect of HCV genotype-specific polymorphisms in Core, NS3, NS5A, and NS5B proteins on T-cell epitope processing and presentation
Mutation
167 27353271 Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
Mutation
168 35456731 Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt
Mutation
169 24708767 Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy
Mutation
170 26282418 Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir
Mutation
171 30464554 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
Mutation
172 30125371 Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r
Mutation
173 25820616 Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins
Mutation
174 21600241 Palindromic-nucleotide substitutions (PNS) of hepatitis C virus genotypes 1 and 5a from South Africa
Mutation
175 31640596 Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study
Mutation
176 29164151 Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
Mutation
177 20624431 Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes
Mutation
178 34479413 Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China
Mutation
179 33924449 Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy
Mutation
180 25266287 Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
Mutation
181 25856426 Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent
Mutation
182 32368162 Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
Mutation
183 24587329 Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein
Mutation
184 25122476 Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423
Mutation
185 33141008 A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir
Mutation
186 26936587 Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs
Mutation
187 24697920 Hepatitis C virus NS3 mutations in haemophiliacs
Mutation
188 27913920 NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b
Mutation
189 27004425 Antiviral response and resistance analysis of treatment-naive HCV-infected patients receiving single and multiple doses of GS-9190
Mutation
190 31523019 Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil
Mutation
191 29856885 The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir
Mutation
192 30577623 Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection
Mutation
193 19026009 Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients
Mutation
194 31273794 Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naive patients from Argentina
Mutation
195 29701642 Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort
Mutation
196 29780135 The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1
Mutation
197 31118701 Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype
Mutation
198 29239718 New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors
Mutation
199 30884449 Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation
Mutation
200 21145839 Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
Mutation
201 22155364 Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease
Mutation
202 24886541 Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
Mutation
203 28132867 Antiviral response and resistance analysis of treatment-naive HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256
Mutation
204 23409973 Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study
Mutation
205 26674563 No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
Mutation
206 26799692 Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
Mutation
207 29084747 In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
Mutation
208 30344416 Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus
Mutation
209 20170366 Functional characterization of core genes from patients with acute hepatitis C virus infection
Mutation
210 21569441 Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
Mutation
211 35571102 Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
Mutation
212 28008868 Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin
Mutation
213 31424972 Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
Mutation
214 29425396 Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors
Mutation
215 32490325 Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
Mutation
216 30754682 Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions
Mutation
217 26778412 High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection
Mutation
218 20630078 Structural studies of Helicase NS3 variants from Hepatitis C virus genotype 3 in virological sustained responder and non-responder patients
Mutation
219 33262618 Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies
Mutation
220 34578414 Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients
Mutation
221 27696653 Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study
Mutation
222 31060315 Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
Mutation
223 37231989 Hepatitis C Virus Genotype 5 Variability in Treatment-Naive Patients in South Africa
Mutation
224 29982508 Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes
Mutation
225 17376913 Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro
Mutation
226 23268692 Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site
Mutation
227 20824094 Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production
Mutation
228 28105744 Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
Mutation
229 32306039 Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM
Mutation
230 17907805 Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein
Mutation
231 22580131 Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors
Mutation
232 23127989 Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors
Mutation
233 26824949 A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin
Mutation
234 30319736 Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach
Mutation
235 40143305 The Genotypes/Subtypes and Antiviral Drug Resistance of the Hepatitis C Virus from Patients in a Tertiary Care Hospital in Nepal
Mutation
236 24755925 Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA
Mutation
237 10488152 Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321
Mutation
238 18369478 Regulation of hepatitis C virion production via phosphorylation of the NS5A protein
Mutation
239 23077515 HCV NS5A protein containing potential ligands for both Src homology 2 and 3 domains enhances autophosphorylation of Src family kinase Fyn in B cells
Mutation
240 23616661 Modulation of hepatitis C virus genome encapsidation by nonstructural protein 4B
Mutation
241 24120570 Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a
Mutation
242 28467359 Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed
Mutation
243 28615203 Phosphorylation of Serine 225 in Hepatitis C Virus NS5A Regulates Protein-Protein Interactions
Mutation
244 32260271 Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
Mutation
245 38781172 Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy
Mutation
246 9344909 Determinants of substrate specificity in the NS3 serine proteinase of the hepatitis C virus
Mutation
247 23315449 Hepatitis C virus NS4B targets lipid droplets through hydrophobic residues in the amphipathic helices
Mutation
248 26587022 Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches
Mutation
249 25243902 Structural analysis of asunaprevir resistance in HCV NS3/4A protease
Mutation
250 28635289 Exploring the Drug Resistance of HCV Protease
Mutation
251 28753979 Lack of Association between Hepatitis C Virus core Gene Variation 70/91aa and Insulin Resistance
Mutation
252 32234812 Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors
Mutation
253 33430709 Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study
Mutation
254 35029245 The Q41R mutation in the HCV-protease enhances the reactivity towards MAVS by suppressing non-reactive pathways
Mutation
255 16945160 Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression
Mutation
256 18421139 Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034
Mutation
257 22768327 Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase
Mutation
258 22910833 The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors
Mutation
259 23594083 Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance
Mutation
260 24100495 In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir
Mutation
261 28577353 Simeprevir with peginterferon alpha-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
Mutation
262 25000830 A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy
Mutation
263 24643004 A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants
Mutation
264 27575432 Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions
Mutation
265 17713156 Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3
Mutation
266 17949436 Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3
Mutation
267 18006035 Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
Mutation
268 18773115 Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness
Mutation
269 19199553 Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual
Mutation
270 21197453 Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses
Mutation
271 21957313 A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus
Mutation